Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables manufacturing sites, with more capacity on the way. With a ribbon-cutting ceremony and tour on June 14, 2024, Lilly showed off its ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

The diabetes drug Ozempic has been a hit for manufacturer Novo Nordisk. But its meteoric rise in popularity brings with it concerns for the patent holder due to emerging reports of patient harm and ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in a trial for its next-generation obesity drug. A drop of 29pc led to as ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...